| Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology MH Shah, WS Goldner, AB Benson, E Bergsland, LS Blaszkowsky, ... Journal of the National Comprehensive Cancer Network 19 (7), 839-868, 2021 | 347 | 2021 |
| NCCN guidelines insights: neuroendocrine and adrenal tumors, version 2.2018 MH Shah, WS Goldner, TR Halfdanarson, E Bergsland, JD Berlin, ... Journal of the National Comprehensive Cancer Network 16 (6), 693-702, 2018 | 336 | 2018 |
| International ranking systems for universities and institutions: a critical appraisal JPA Ioannidis, NA Patsopoulos, FK Kavvoura, A Tatsioni, E Evangelou, ... BMC medicine 5, 1-9, 2007 | 187 | 2007 |
| Falsified papers in high-impact journals were slow to retract and indistinguishable from nonfraudulent papers NA Trikalinos, E Evangelou, JPA Ioannidis Journal of clinical epidemiology 61 (5), 464-470, 2008 | 118 | 2008 |
| Real‐world use and survival outcomes of immune checkpoint inhibitors in older adults with non–small cell lung cancer B Youn, NA Trikalinos, V Mor, IB Wilson, IJ Dahabreh Cancer 126 (5), 978-985, 2020 | 67 | 2020 |
| Systemic therapy for combined hepatocellular-cholangiocarcinoma: a single-institution experience NA Trikalinos, A Zhou, MBM Doyle, KJ Fowler, A Morton, N Vachharajani, ... Journal of the National Comprehensive Cancer Network 16 (10), 1193-1199, 2018 | 50 | 2018 |
| Defactinib, pembrolizumab, and gemcitabine in patients with advanced treatment refractory pancreatic cancer: a phase I dose escalation and expansion study A Wang-Gillam, KH Lim, R McWilliams, R Suresh, AC Lockhart, A Brown, ... Clinical Cancer Research 28 (24), 5254-5262, 2022 | 41 | 2022 |
| The elderly were under-represented in osteoarthritis clinical trials G Liberopoulos, NA Trikalinos, JPA Ioannidis Journal of clinical epidemiology 62 (11), 1218-1223, 2009 | 34 | 2009 |
| Association of preoperative monocyte‐to‐lymphocyte and neutrophil‐to‐lymphocyte ratio with recurrence‐free and overall survival after resection of pancreatic neuroendocrine … RZ Panni, AG Lopez‐Aguiar, J Liu, GA Poultsides, FG Rocha, ... Journal of Surgical oncology 120 (4), 632-638, 2019 | 33 | 2019 |
| Enterochromaffin-like cell hyperplasia–associated gastric neuroendocrine tumors may arise in the setting of proton pump inhibitor use: the need for a new clinicopathologic category R Rais, NA Trikalinos, J Liu, D Chatterjee Archives of Pathology & Laboratory Medicine 146 (3), 366-371, 2022 | 21 | 2022 |
| Effect of metastatic site on survival in patients with neuroendocrine neoplasms (NENs). An analysis of SEER data from 2010 to 2014 NA Trikalinos, BR Tan, M Amin, J Liu, R Govindan, D Morgensztern BMC Endocrine Disorders 20, 1-10, 2020 | 20 | 2020 |
| FOLFIRINOX for the treatment of advanced gastroesophageal cancers: a phase 2 nonrandomized clinical trial H Park, RU Jin, A Wang-Gillam, R Suresh, C Rigden, M Amin, BR Tan, ... JAMA oncology 6 (8), 1231-1240, 2020 | 20 | 2020 |
| Comparative efficacy of first-line therapies for advanced-stage chronic lymphocytic leukemia: a multiple-treatment meta-analysis T Terasawa, NA Trikalinos, B Djulbegovic, TA Trikalinos Cancer treatment reviews 39 (4), 340-349, 2013 | 15 | 2013 |
| Phase Ib study of ulixertinib plus gemcitabine and nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma PM Grierson, B Tan, KS Pedersen, H Park, R Suresh, MA Amin, ... The Oncologist 28 (2), e115-e123, 2023 | 14 | 2023 |
| Abstract CT118: Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer: Experiences of pancreatic ductal adenocarcinoma (PDAC … A Wang-Gillam, R McWilliams, AC Lockhart, BR Tan, R Suresh, KH Lim, ... Cancer Research 80 (16_Supplement), CT118-CT118, 2020 | 13 | 2020 |
| Neuroendocrine and adrenal tumors, version 2.2018 featured updates to the nccn guidelines MH Shah, WS Goldner, TR Halfdanarson, E Bergsland, JD Berlin, ... JNCCN Journal of the National Comprehensive Cancer Network 16 (6), 693-702, 2018 | 12 | 2018 |
| Neuroendocrine tumors of the lung S Randhawa, N Trikalinos, GA Patterson Thorac Surg Clin 31 (4), 469-476, 2021 | 11 | 2021 |
| Intratumoral fibrosis and tumor growth pattern as prognostic factors in optimally resected pancreatic neuroendocrine neoplasms: an analysis of 168 cases D Chatterjee, NA Trikalinos, GA Williams, J Liu, WG Hawkins, C Hammill Pancreas 49 (2), 255-260, 2020 | 11 | 2020 |
| LBA53 Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET) J Chan, S Geyer, FS Ou, M Knopp, S Behr, T Zemla, J Acoba, A Shergill, ... Annals of Oncology 34, S1292, 2023 | 10 | 2023 |
| A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors H Park, K Williams, NA Trikalinos, S Larson, B Tan, S Waqar, R Suresh, ... Cancer chemotherapy and pharmacology 87, 337-347, 2021 | 10 | 2021 |
Kian-Huat LimWashington University School of Medicine在 dom.wustl.edu 的电子邮件经过验证
